Abstract

Overview

Late Onset Alzheimer's Disease is the most common cause of dementia, characterized by the accumulation of neurotoxic plaques primarily consisting of amyloid-β (Aβ) peptide and tau protein tangles.

Findings

• Data supports the use of repeated electromagnetic field stimulation (REMFS) as a noninvasive approach to decrease Aβ levels in primary human brain cultures.
• Effects of REMFS were tested on Aβ levels in varying lengths (Aβ40 and Aβ42) under different electromagnetic frequencies, powers, and specific absorption rates (SAR).
• Significant reduction in Aβ levels was observed in cultures treated at 64 MHz, for 1-2 hours daily across several timeframes, with a minimum effective SAR of 0.4 W/kg.
• No evident cellular toxicity or significant alterations in secreted amyloid precursor protein-α (sAPPα) levels were noted, indicating that reduction of Aβ levels was not due to a shift towards the α-secretase pathway.

Conclusion

The REMFS parameters used are similar to those employed in human MRI, suggesting potential for clinical application to modulate neurodegenerative plaque deposition.